Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This toxicity is often related to the partial or complete d...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Alfonso, P., Saiz-Rodríguez, M., Mondéjar, R., Salazar, J., Páez, D., Borobia, A. M., Safont, M. J., García-García, I., Colomer, R., García-González, X., Herrero, M. J., López-Fernández, L. A., Abad-Santos, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Special Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885558/
https://www.ncbi.nlm.nih.gov/pubmed/34773566
http://dx.doi.org/10.1007/s12094-021-02708-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885558/
https://www.ncbi.nlm.nih.gov/pubmed/34773566
http://dx.doi.org/10.1007/s12094-021-02708-4

Ejemplares similares